BioInsights Raises $2.8M Series A Funding

Neela Biotech

Neela Biotech is building a scalable pathway to sustainable fuels and chemicals at fossil cost parity, enabling a more circular, resilient, and energy-secure future. 🧪 Our proprietary Controlled Microbial Upcycling leverages advances in AI and synthetic biology to convert waste into renewable feedstocks for fuels and chemicals. By working within existing biogas infrastructure, our approach is designed to scale more easily and at lower costs than many alternative pathways. ✈️ Our beachhead market is Sustainable Aviation Fuel (SAF) where our platform chemical feeds into HEFA-SAF, opening up a practical route to scale one of the most commercially mature SAF pathways. 🚀 We are part of the IAG innovation program, have secured grants from Innovate UK and the Henry Royce Institute, and are backed by Founders at the University of Cambridge’s Start 3.0, Undaunted’s Greenhouse and Fifty Years’ 5050. Enquiries: info@neelabiotech.com

IMMIX

Stablecoin liquidity is concentrated in dollars. IMMIX is an AI-native trading firm that makes markets in non-USD stablecoin FX, trading as principal. Outside dollar markets, fragmented liquidity turns a single conversion into multiple FX legs, intermediary transfers, prefunding and stacked desk fees. A thin pair has too little data to price on its own, so most desks quote the dollar pairs and leave the rest. We develop and apply state-of-the-art deep learning to close that gap. Models forecast market states for 10,000+ instruments from 30+ sources, so the desk can price a market into a counterparty where no direct market exists. A portfolio optimiser sets price, hedge and execution together across the whole book. Models forecast, estimate and inform. The desk prices, quotes, holds and hedges. One desk. Three kinds of partner. Payment firms: one FX transaction per payment, priced and executed as principal. Stablecoin issuers: a direct market for your asset, built and operated by the desk. Venues and platforms, including FX brokers and investment platforms: two-sided principal liquidity on the pairs your venue lists. Founded by Andrew Mann, PhD and David Twomey, PhD. Team previously at Virtu Financial, J.P. Morgan, DV Trading, UBS, Morgan Stanley, ICE, Bank of England, UCL and the University of Cambridge. Backed by MassMutual Ventures, Ripple, Crane Venture Partners, Portfolio Ventures and BTSE. 10,000+ instruments modelled: unique instruments in the IMMIX instrument model, as of 22 August 2026; not tradable or offered instruments. 30+ sources: integrated market-data sources; not all simultaneously live or used for every market. $25B+ traded: cumulative traded notional through IMMIX infrastructure, as of 22 August 2026; infrastructure history, not desk volume. Better markets begin with better models.